{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"castrate metastatic prostate cancer","name":"PSMACare","nct_id":"NCT01140373","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=psmacare-nct01140373. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.","label":"autologous T cells & cyclophosphamide.","type":"EXPERIMENTAL"}],"collaborators":["United States Department of Defense"],"completion_date":{"date":"2027-06","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":13,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"engineered autologous T cells","otherNames":[],"type":"BIOLOGICAL"},{"name":"cyclophosphamide","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-07","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"The safety and tolerability of immunotherapy","timeFrame":"4 weeks"}],"references":[],"start_date":{"date":"2010-06"},"study_type":"INTERVENTIONAL","title":"Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)","url":"https://clinicaltrials.gov/study/NCT01140373"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/psmacare-nct01140373"}